Video Player

Invivyd is developing antibodies to transcend the limits of naturally occurring immunity and provide higher levels of protection from viral diseases, beginning with COVID-19

We are driven to change the paradigm for combatting viral infection by delivering rapid and lasting antibody immunity to protect the general public and ensure vulnerable populations are never left behind.

Investor Relations

About Invivyd

(Nasdaq: IVVD)
Invivyd, Inc., is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd's technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit invivyd.com to learn more.